Scisparc Ltd. · NASDAQ:SPRC
Scisparc — Therapix Biosciences — IPO Roadshow (March 2017)
21 slides from Scisparc's IPO roadshow presentation, Mar 20, 2017
Slide 1: Clinical-Stage Pharmaceutical Company Focusing on Proprietary Synthetic Cannabinoids
1 Clinical - Stage Pharmaceutical Company Focusing on Proprietary Synthetic Cannabinoids Technologies Developed in Israel March 2017 Issurer Free Writing Prospectus dated March 20 , 2017 Filed Pursuant to Rule 433 Registration Statement No. 333 - 214458
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation constitutes a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained by Therapix Biosciences Ltd . (“we”, “us” or “our”) under Rule 433 to the Securities Act of 1933 , as amended, or the Ac
Slide 3: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the offering to which this communication relates . Because it is a summary , it does not contain all of the information that you should consider before investing in our securities . We have filed a regist
Slide 4: Company Highlights
x Clinical - stage pharmaceutical company x Repurposing FDA approved synthetic THC (dronabinol) x Proprietary formulations , dosage and delivery platforms x Novel sublingual and nasal THC formulations x Focused on high - reward CNS indications x Combining two development programs: x Tourette Syndrom
Slide 5: Management Team
Dr . Ascher Shmulewitz, Chairman - P rolific inventor and serial entrepreneur in biomedical technologies - H as founded over two dozen life science companies and l ed multiple companies to successful exits Dr. Elran Haber , CEO - Served more than 10 years as Chairman and on Board Director s of sever
Slide 6: Board of Directors
Dr. Yafit Stark , Independent Director - VP & Global Clinical Advisor, Global Clinical Development at Teva Pharmaceuticals Ltd. - E stablished the Innovative R&D Division of Teva USA - Was res ponsible for the clinical development of Copaxone Mr. Avi Meizler , Director - E xperienced businessman a
Slide 7: Cannabis and Cannabinoid Overview
M edicinal use of c annabis and derivatives is well known 1 Best known agents in cannabis : THC and CBD x Potential b enefits shown in multiple indications: antispastic, analgesic, antiemetic, neuroprotective, anti - inflammatory and in certain psychiatric diseases 1 x Sourced botanically (complex
Slide 8: Repurposing FDA Approved Cannabinoid (THC) For New Indications
Repurposing FDA Approved Cannabinoid (THC) For New Indications 8 Tourette Syndrome Therapy based on the “ Entourage Effect ” The “ Entourage Effect ” first described by Prof. Raphael Mechoulam 1 Cognitive Deterioration / Pre - Alzheimer's “ Ultra - Low Dose THC ” A systemic cannabinoid - based thera
Slide 9: Entourage Effect – THC and PEA
“ Entourage Effect ” – THC and PEA 9 THC and PEA, a Proprietary Combination The Entourage Effect
Slide 10: Targeting Tourette Syndrome, an Orphan Disease
x Primary near - term indication for Therapix : Tourette Syndrome - A neuropsychiatric tic disorder characterized by motor and vocal tics x To date, only three drugs have been approved by the FDA to treat Tourette Syndrome - limited use due to severe side effects x THC shown to reduce Tourette ’ s s
Slide 11: Tourette Syndrome - Joint Pharma Solution THX-TS
Tourette Syndrome - Joint Pharma Solution THX - TS 01 x Several studies suggest that cannabis and THC may be effective in the treatment of Tourette Syndrome x THX - TS 01 - combines a synthetic endo cannabinoid analog , PEA , with THC x Taking a 505 (b)( 2 ) regulatory strategy for FDA approval,
Slide 12: Tourette Syndrome - THX-TS Development Plan
Tourette Syndrome - THX - TS 01 Development Plan J o i Note: The Company ’ s assessments and estimations regarding the abovementioned time table and regulatory approvals required for the research and dev elopment of the product and the relative described milestones, including without limitation, the
Slide 13: THX-TS - Additional Opportunities
THX - TS 01 - Additional Opportunities x Antimicrobial resistance has been defined as a global threat 1,2 x Urgent unmet need for new anti - bacterial agents 2 x THC may possess antibacterial properties, which were assessed in number of clinically relevant applications 3 x Therapix intends to use it
Slide 14: Mild Cognitive Impairment (MCI) and Alzheimer's Disease
x In 2015 , there were an estimated 46.8 million people with dementia worldwide and is estimated to increase by 2030 to 74.7 million 1 x The global societal economic cost of dementia for 2015 is estimated at $ 818 billion, a 35 % increase from the cost estimate for 2010 1 x The prevalence of Mild Co
Slide 15: Cannabis and Cognition
x Cannabis has been s hown to cause long - term cognitive deficits in chronic users manifested as impairment in attention, memory or executive functions x Paradoxically, Ultra - Low Doses of THC have been shown to prevent and reverse cognitive decline in preclinical trials 1 as d emonstrated by Prof
Slide 16: Mild Cognitive Impairment (MCI) - BrainBright Solution THX-ULD 01
x Recent pre - clinical research demonstrates Ultra - Low Doses of THC can prevent cognitive impairment x THX - ULD 01 - Therapix is developing a unique drug based on an FDA approved synthetic cannabinoid for delaying memory loss and potential progression to early stages of Alzheimer ’ s x Regulat
Slide 17: MCI - THX-ULD 01 Development Plan
Note: The Company ’ s assessments and estimations regarding the abovementioned time table and regulatory approvals required for the research and dev elopment of the product and the relative described milestones, including without limitation, the regulatory path required to obtain FDA approval and th
Slide 18: Scientific Advisory Board
Prof. Raphael Mechoulam - A Professor Emeritus of the School of Pharmacy at the Faculty of Medicine of the Hebrew University in Jerusalem - A recipient of the Israel Prize Prof. James Leckman - A child Psychiatrist at Yale University - S erved as Director of the Child Study Center at Yale for over t
Slide 19: FDA-Regulated Drugs vs. Medical Marijuana
FDA - regulated drugs vs. medical marijuana x Medical marijuana: variable dosing; therapeutic and psychoactive effects; poor compliance ; abuse potential; political issues (still considered as Schedule 1 drug) x FDA - regulated drugs: Rigorous GMP manufacturing; clinical efficacy/safety studies; c
Slide 20: Summary
Summary 20 x Focused on high value CNS indications with unique combinations, formulations and delivery methods x Two indications with potential for shorter regulatory paths due to: Orphan Drug Designation (Tourette ’ s) and 505 (b)( 2 ) pathway using approved active ingredients (Tourette's, MCI) x P
Slide 21: Therapix Biosciences Ltd. contact details
21 Therapix Biosciences Ltd. 5 Azrieli Center (Square Tower) 27 Fl. Tel - Aviv 6702501 , Israel Tel: + 972 - 3 - 6167055 www.therapixbio.com